๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 451 Beijing 25 Shenzhen 23 Zhongshan 17 Nanning 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281 Clear sponsor filter
Site location
Guangzhou451 Beijing25 Shenzhen23 Zhongshan17 Nanning17
All 55 locations
Target enrolment
to
490 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
NCT07294261Local Advanced or Metastatic NSCLC
Sun Yat-sen University
Phase 2
69
Guangzhou
2025-12-23
Not yet open
SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer
NCT07297030Rectal Cancer
Sun Yat-sen University
Phase 2
37
Guangzhou
2025-12-20
Not yet open
Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
NCT07347119Central Serous Chorioretinopathy (CSC)
Sun Yat-sen University
Observational
120
Guangzhou
2025-12-18
Active, closed
Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07374003Locally Advanced, Resectable
Sun Yat-sen University
Phase 2
62
Guangdong
2025-12-17
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Not yet open
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
NCT07261709Refractory Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
236
Guangzhou
2025-12-01
Recruiting
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
NCT07269899Solid Tumor Cancer, Cancer
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-11-25
Not yet open
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
NCT07254156Colorectal Cancer, MRD, ctDNA
Sun Yat-sen University
Observational
229
Guangzhou
2025-11-24
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
25
Guangzhou
2025-11-21
Recruiting
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
NCT07241793Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent
Sun Yat-sen University
Phase 2
96
Guangzhou, Wuhan, Nanchang, Kunming
2025-11-20
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
NCT07258108Breast Cancer
Sun Yat-sen University
Phase 2
35
Guangzhou
2025-11-13
Recruiting
Adaptive Immunotherapy for Nasopharyngeal Carcinoma
NCT07154069Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
802
Guangzhou
2025-11-13
Recruiting
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
NCT07238881Hepatocellulcar Carcinoma
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-11-05
By invitation
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
NCT07488572Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Phase 2
60
Guangzhou
2025-11-01
Active, closed
Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
NCT07538180Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-10-30
Recruiting
Risk Factors Affecting MSC Efficacy in ACLF Patients
NCT07198854Acute-On-Chronic Liver Failure
Sun Yat-sen University
Observational
446
Guangzhou
2025-10-20
Recruiting
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
NCT07101744Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
41
Guangdong
2025-10-17
Not yet open
Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer
NCT07170982Endometrial Cancer
Sun Yat-sen University
Phase 2
128
Guangzhou
2025-10-15
Not yet open
Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children
NCT07137884Rhabdomyosarcoma Recurrent, Maintenance Treatment
Sun Yat-sen University
Phase 2
150
Guangzhou
2025-10-01
Not yet open
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
NCT07103408Small-Cell Lung Cancer (SCLC)
Sun Yat-sen University
Phase 2
56
Guangzhou
2025-10-01
Not yet open
The IVO-LUNG Study
NCT07204548Non Small Cell Lung Cancer (Stage III)
Sun Yat-sen University
Phase 2
63
Guangzhou
2025-10
Recruiting
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
NCT06939855Bone and Soft Tissue Tumors
Sun Yat-sen University
Phase 2
45
Guangzhou
2025-09-28
Not yet open
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
NCT07145931Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
Sun Yat-sen University
Phase 2
24
Guangzhou
2025-09-20
Recruiting
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
NCT07192185Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-17
Not yet open
A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery.
NCT07141147Radiotherapy, High-risk Localized Adrenocortical Carcinoma
Sun Yat-sen University
Not applicable
58
Guangzhou
2025-09-15
Recruiting
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
NCT07077512Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-15
Recruiting
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
NCT07088263Breast Neoplasms
Sun Yat-sen University
Phase 3
192
Guangzhou
2025-09-15
Recruiting
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
NCT07084662Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2/3
80
Guangzhou
2025-09-11
Recruiting
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
NCT07177794Esophageal Cancer, Chemoradiotherapy
Sun Yat-sen University
Phase 3
242
Guangzhou
2025-09-10
Recruiting
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
NCT07093710Peripheral T Cell Lymphoma
Sun Yat-sen University
Phase 1/2
101
Guangzhou
2025-08-27
Not yet open
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07138989Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
10
Guangzhou
2025-08-19
Not yet open
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma
NCT07110558Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
59
Guangzhou
2025-08-15
Recruiting
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma
NCT07125755Squamous Cell Cancer of Head and Neck (SCCHN)
Sun Yat-sen University
Phase 3
386
Guangzhou, Guilin, Sanya, Changsha, Nanjing
2025-08-15
Active, closed
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
NCT07138885Hepatocellular Carcinoma (HCC), Second Line Treatment
Sun Yat-sen University
Phase 2
62
Guangzhou
2025-08-01
Not yet open
Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component
NCT07060599Artificial Intelligence (AI) in Diagnosis
Sun Yat-sen University
Not applicable
480
Guangzhou
2025-08-01
Recruiting
Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
NCT07337811Rectal Cancer Patients
Sun Yat-sen University
Not applicable
27
Guangzhou
2025-08-01
Active, closed
Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma
NCT07488533Non-Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Phase 2
40
Guangzhou
2025-08-01
Recruiting
Mechanism and Effect of Novel Metabolites on Valvular Heart Disease
NCT07065500Valvular Heart Disease
Sun Yat-sen University
Observational
4,000
Guangzhou
2025-08-01
Not yet open
Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
NCT07129161Carcinoma, Non-Small-Cell Lung
Sun Yat-sen University
Phase 2
66
Guangzhou, Xi'an
2025-08
Recruiting
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT07086456Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy, Consolidation Therapy
Sun Yat-sen University
Phase 2
80
Guangzhou
2025-07-20
Recruiting
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07086469Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy, Chemoradiotherapy
Sun Yat-sen University
Phase 2
69
Guangzhou
2025-07-20
Recruiting
Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm
NCT07066891Diabetes Mellitus, Type 2 Diabetes
Sun Yat-sen University
Not applicable
400
Guangzhou
2025-07-15
Not yet open
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
NCT07059338HER2 Positive, Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 2
34
Guangzhou
2025-07-11
Recruiting
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
NCT07386158Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
21
Guangzhou
2025-07-10
Active, closed
Artificial Intelligence Diagnosis of Different Histopathological Growth Patterns of Colorectal Cancer Liver Metastasis
NCT07088393Liver Metastases of Colorectal Cancer
Sun Yat-sen University
Observational
437
Guangzhou
2025-07-09
Recruiting
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
NCT06802835Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2
148
Guangzhou
2025-07-09
Recruiting
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
NCT07064681Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Sun Yat-sen University
Observational
100
Guangzhou
2025-07-05
Recruiting
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
NCT07052669Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
311
Chongqing, Lanzhou, Guangzhou
2025-07-01
Not yet open
ScreenTalk to Improve Colorectal Cancer Screening Uptake Among First-degree Relatives of Patients: a Study Protocol
NCT06710860Colonoscopy, Colorectal Cancer, First-degree Relatives
Sun Yat-sen University
Not applicable
314
Guangzhou
2025-07
Not yet open
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
NCT07032532Peripheral T Cell Lymphoma
Sun Yat-sen University
Phase 2
35
Guanzhou
2025-07
Recruiting
Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision
NCT07651553Rectal Cancer Patients, Robotic Assisted Intervention
Sun Yat-sen University
Not applicable
216
Guangzhou
2025-06-30
Active, closed
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
NCT06673693Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC
Sun Yat-sen University
Phase 2
24
Guangzhou
2025-06-25
Recruiting
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
NCT06947811EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Sun Yat-sen University
Phase 1/2
71
Guangzhou
2025-06-09
Recruiting
Omitting CTV for Primary Tumor in LS-SCLC
NCT07008716SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect, Progression
Sun Yat-sen University
Phase 3
852
Guangzhou, Hangzhou
2025-06-03
Recruiting
Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
NCT06903858Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency
Sun Yat-sen University
Phase 2
105
Guangzhou
2025-06-01
Active, closed
Pelvic Floor Peritoneal Closure to Prevent Postoperative Ileus in Mid-Low Rectal Cancer Surgery
NCT07432542Rectal Cancer Surgery, Middle and Low Rectal Cancer, Intestinal Obstruction, Ileus
Sun Yat-sen University
Not applicable
516
Guangzhou
2025-06-01
Not yet open
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-ฮฒand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
NCT06959693Metastatic Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 2/3
590
Guangzhou
2025-06-01
Not yet open
New Triple Therapy in Newly Diagnosed Type 2 Diabetes
NCT06946628Diabetes Mellitus
Sun Yat-sen University
Phase 3
296
Guangzhou
2025-06-01
Recruiting
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
NCT07150247BRAF V600 Colorectal Cancer
Sun Yat-sen University
Phase 2
20
Guangzhou
2025-06-01
Recruiting
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
NCT07012954Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 1/2
64
Guangzhou
2025-06-01
Recruiting
Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial
NCT07512232Middle and Low Rectal Cancer, Rectal Cancer Surgery
Sun Yat-sen University
Not applicable
1,598
Guangzhou
2025-06-01
Recruiting
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
NCT06912711Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
70
Guangzhou
2025-05-16
Recruiting
Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers
NCT06966232Gastrointestinal Cancers
Sun Yat-sen University
Phase 3
136
Guangzhou
2025-05-15
Recruiting
Safety and Efficacy of Pucotenlimab in pLECC
NCT06969534Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma
Sun Yat-sen University
Phase 2
33
Guangzhou
2025-05-15
Recruiting
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
NCT06977074Non-small Cell Lung Cancer (NSCLC)
Sun Yat-sen University
Phase 2
83
Guangzhou
2025-05-10
Recruiting
Risk Assessment for HBV-Related Liver Cancer
NCT07160946HBV-related Liver Cirrhosis
Sun Yat-sen University
Observational
6,000
Guangzhou
2025-05-10
Not yet open
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
NCT06861712Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-05-06
Recruiting
An AI Educational Agent for Medical Machine Learning Courses
NCT07449182Medical Education, Artificial Intelligence in Medicine
Sun Yat-sen University
Not applicable
56
Guangzhou
2025-05-01
Not yet open
Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma
NCT06429397Pheochromocytoma
Sun Yat-sen University
Phase 2
22
Guangzhou
2025-05-01
Not yet open
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
NCT06961500Follicular Lymphoma Grade 3A
Sun Yat-sen University
Phase 2
133
Guangzhou
2025-05-01
Not yet open
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
NCT06900218Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
664
Guangzhou
2025-05-01
Not yet open
Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
NCT06957561Bladder Cancer, Muscle-invasive Bladder Cancer
Sun Yat-sen University
Phase 1/2
30
Guangzhou
2025-04-30
Recruiting
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
NCT06911684Rectal Cancer Patients
Sun Yat-sen University
Phase 2
88
Guangzhou
2025-04-30
Recruiting
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC๏ผˆARMOR2501๏ผ‰
NCT06924398Lung Cancer (NSCLC)
Sun Yat-sen University
Phase 2
32
Guangzhou
2025-04-20
Not yet open
GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
NCT06605131Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
72
Guangzhou
2025-04-17
Recruiting
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
NCT06827717Ewing Sarcoma
Sun Yat-sen University
Phase 2
29
Guangzhou
2025-04-15
Recruiting
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
NCT06846489Mantle Cell Lymphoma (MCL)
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-04-14
Recruiting
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
NCT07188311Hepatoblastoma, Pediatric Cancer
Sun Yat-sen University
Not applicable
24
Guangdong
2025-04-10
Recruiting
A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
NCT06686459Breast Cancer Invasive
Sun Yat-sen University
Not applicable
860
Guangzhou
2025-04-06
Recruiting
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
NCT06912074Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
134
Guangzhou
2025-04-05
Not yet open
Liver Cancer Prognosis Investigation Study
NCT06623734Liver Neoplasms
Sun Yat-sen University
Observational
5,000
Guangzhou
2025-04-01
Recruiting
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
NCT06898385Pancreatic Cancer
Sun Yat-sen University
Phase 1
9
Guangzhou
2025-03-27
Recruiting
Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase โ…ก Single-Arm Study for Resectable Mucosal Melanoma
NCT07336979Resectable Mucosal Melanoma
Sun Yat-sen University
Phase 2
32
Guangzhou
2025-03-20
Recruiting
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
NCT06587802Adrenocortical Carcinoma
Sun Yat-sen University
Phase 2
18
Guangzhou
2025-03-14
Recruiting
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
NCT06854250Metastatic Prostate Cancer
Sun Yat-sen University
Phase 2
104
Guangzhou
2025-03-01
Recruiting
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
NCT06793956Extranodal Natural Killer/T Cell Lymphoma
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-02-21
Active, closed
Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.
NCT06854510Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2/3
196
Guangzhou
2025-02-21
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
NCT06831357Nasopharyngeal Cancinoma (NPC), Distant Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2025-02-15
Not yet open
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naรฏve Follicular Lymphoma
NCT06757894Follicular Lymphoma (FL)
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-02-01
Recruiting
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
NCT06855823Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University
Phase 1/2
33
Guangzhou
2025-01-14
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
NCT06760039Diffuse Large B-Cell Lymphoma
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
NCT06737913Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2
76
Lanzhou, Guangzhou, Zhengzhou
2025-01-03
Recruiting
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
NCT06851247Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
47
Guangzhou
2025-01-03
Not yet open
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
NCT06739317Unresectable Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2/3
398
Guangzhou
2025-01-01
Recruiting
Probiotics in Advanced Urothelial Carcinoma
NCT06904573Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
Sun Yat-sen University
Phase 2
222
Guangzhou, Wuhan
2025-01-01
Recruiting
TACE Combined Surgery for the Resectable Huge HCC
NCT06898398Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
Sun Yat-sen University
Observational
326
Beijing
2025-01-01
Recruiting
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647Metastatic Breast Cancer, Recurrent Breast Cancer
Sun Yat-sen University
Phase 1
20
Guangzhou
2025-01-01
Not yet open
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
NCT06646211Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-01-01
Rows per page Showing 101–200 of 490
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.